Evidence map›Paper›PMID 41431931›Full record

ArticleEuropean heart journal2026

Cardiac sarcoidosis: new insights beyond the granuloma using spatial proteomics.

Eliot G Peyster, David Smith, Therese Bittermann, Paco E Bravo, Kenneth B Margulies

Abstract read
In one paragraph

Article in European heart journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Eliot G PeysterWesley Research Institute, Level 8, East Wing, The Wesley Hospital, 451 Coronation Dr, Auchenflower, QLD 4066, Australia.ORCID 0000-0002-3350-3136
David SmithChildren's Hospital of Philadelphia Single Cell Technology Core, Ruth and Tristram Colket Jr. Translational Research Building, Level A, Rooms A450D, 3501 Civic Center Blvd, Philadelphia, PA 19104, USA.
Therese BittermannDepartment of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, 423 Guardian Dr, Philadelphia, PA 19104, USA.ORCID 0000-0002-8576-0193
Paco E BravoDivision of Cardiovascular Medicine, University of Pennsylvania, Perelman Center for Advanced Medicine, 11th floor, 3400 Civic Center blvd, Philadelphia, PA 19104, USA.ORCID 0000-0002-0022-4376
Kenneth B MarguliesCardiovascular Institute, University of Pennsylvania, Smilow TRB, 11th floor, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA.ORCID 0000-0002-8093-4465

Funding

Personalized Risk Prediction and Mechanistic Profiling of Cardiac Allograft VasculopathyR01HL170152 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Eliot Peyster · 2025 to 2026
$1.3M
Personalized Rejection Risk Assessment in Cardiac TransplantationK08HL159344 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI PEYSTER, ELIOT · 2021 to 2024
$667k
Bogle Family FoundationFoundation for Sarcoidosis ResearchNational Heart, Lung and Blood Institute K08HL159344National Heart, Lung and Blood Institute R01HL15807101A1NHLBI NIH HHS K08 HL159344NHLBI NIH HHS R01 HL170152
6 · The paper itself

Abstract

BACKGROUND AND

aimsCardiac sarcoidosis (CS) is poorly understood, challenging to diagnose, and portends a poor prognosis. A lack of animal models necessitates the use of residual human samples to study sarcoidosis, which in turn necessitates the use of analytical tools compatible with archival, fixed tissue. This study employed high-plex spatial protein analysis to characterize the immunologic, fibrotic, and metabolic landscape of CS.

methodsCardiac tissues from 64 patients-39 with CS and 25 without CS (Controls)-were analysed using the GeoMx Digital Spatial Profiler. Regions of interest (ROIs) with and without granulomatous inflammation were selected to examine protein abundance. ROIs were further divided into areas of illumination to separately analyse distinct protein profiles in myocytes, stroma, and vessels. A 79-protein panel was used to characterize immune and parenchymal cell populations. Differential protein abundance was evaluated using mixed-effects modeling. A predictive model was developed using a subset of seven proteins to distinguish inflammation-free CS ROIs from control ROIs.

resultsSpatial profiling demonstrated marked heterogeneity within and between sarcoidosis granulomas. Inflammation-free ROIs from CS hearts exhibited a 'distance gradient', with protein abundance varying by proximity to granulomatous inflammation. The seven-protein predictive model achieved 95.9% accuracy and an area under the receiver operating characteristic curve of 0.993 in differentiating inflammation-free CS ROIs from Controls.

conclusionsSpatial proteomics revealed novel features of the CS microenvironment and identified a distinct immune signature in tissue lacking overt inflammation. These findings may improve diagnostic accuracy in clinical biopsies from patients with suspected CS.

Indexed as

CardiomyopathiesGranulomaProteomicsSarcoidosisAdultCase-Control StudiesFemaleHumansMaleMiddle AgedMyocardiumCardiomyopathyDiagnosisImage analysisImmune profilingMyocarditisPrecision medicineProteomicsSarcoidosisSpatial biology

Identifiers

PMID41431931
PMCPMC13286639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.